Leerink Partners analyst, Michael Schmidt, reiterated his Outperform on ARIAD Pharmaceuticals (NASDAQ: ARIA) after abstracts were published for presentations that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE